| Name | Title | Contact Details |
|---|
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis` product portfolio and rights are highlighted by a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and intellectual property and knowhow related to the GEAR™ cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis` business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. The Company is headquartered in Wexford, PA.
Extreme Performance Inc is a Littleton, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Novel therapeutics for metabolic and endocrine disorders
DM Clinical Research is a clinical research company that connects pharmaceutical and research organizations to individuals seeking to power the advancement of medicine. They specialize in multiple therapeutic areas in Phase I-IV clinical trials.
Novadoz Pharmaceuticals is a sales and marketing subsidiary for MSN Labs portfolio of finished dosage forms. MSN Labs is a global leader in the development and manufacturing of APIs (active pharmaceutical ingredients).